Neisseria Meningitidis Polysaccharide Conjugated To Tetanus Toxoid

Summary

Neisseria Meningitidis Polysaccharide Conjugated To Tetanus Toxoid (CHEMBL6068498) is an approved vaccine component; indicated across 2 conditions including meningococcal meningitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068498
Name	Neisseria Meningitidis Polysaccharide Conjugated To Tetanus Toxoid
Type	Vaccine component
Max phase	4

Also known as: Menquadfi, Nimenrix

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
meningococcal meningitis	4	MONDO:0018059	EFO:1001040

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	3
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00514904	PHASE3	COMPLETED	Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
NCT01266993	PHASE3	COMPLETED	Persistence and Booster Study of GSK Biologicals’ Meningococcal Vaccine (GSK134612) in Healthy Children
NCT01839175	PHASE3	COMPLETED	Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
NCT04819113	PHASE3	COMPLETED	Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age
NCT07286370	PHASE2	RECRUITING	A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
NCT00715910	PHASE2	COMPLETED	The Long-term Antibody Persistence of GSK Biologicals’ Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults
NCT03606512	PHASE1/PHASE2	COMPLETED	A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age
NCT04645966	PHASE2	TERMINATED	A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
NCT05743881	PHASE1	ACTIVE_NOT_RECRUITING	A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).